Mark S Segal, MD, PhD - Research

Research at a glance

Top areas of exploration

Cells, Cultured , 19 publications
Biomarkers , 17 publications
Kidney Failure, Chronic , 16 publications
Hypertension , 16 publications

Research activity

161 publications

10,466 citations

Why is this important?

Active clinical trials

HyperQure RDN System

HQ-HTN-G01 is a prospective, multicenter, single arm, open label, early feasibility study to evaluate initial safety and device design concept of "HyperQureTM RDN System", laparoscopic renal denervation therapy, in patients with resistant鈥�

Investigator: Mark S Segal
Status: Accepting Candidates
Ages: 22 Years - 80 Years
Sexes: All

EASi-KIDNEY

Investigator: Mark S Segal
Status: Accepting Candidates

REGEN-006

The purpose of this study is to assess the safety and efficacy (including durability) of up to 2 REACT injections given 3 months (+30 days) apart and delivered percutaneously into biopsied and non-biopsied contralateral kidneys in participants with鈥�

Investigator: Mark S Segal
Status: Accepting Candidates
Ages: 30 Years - 80 Years
Sexes: All

My publications

161 publications

2014

Uric acid inhibition of dipeptidyl peptidase IV in vitro is dependent on the intracellular formation of triuret.

Experimental cell research

鈥�

2014

Vasoreparative dysfunction of CD34+ cells in diabetic individuals involves hypoxic desensitization and impaired autocrine/paracrine mechanisms.

PloS one

鈥�

2013

Evaluation of stability and sensitivity of cell fluorescent labels when used for cell migration.

Journal of fluorescence

鈥�

2013

Foods with added fiber lower serum creatinine levels in patients with chronic kidney disease.

Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation

鈥�

2013

Long-term type 1 diabetes influences haematopoietic stem cells by reducing vascular repair potential and increasing inflammatory monocyte generation in a murine model.

Diabetologia

鈥�

网红黑料